Member Info for Dibs61

Richard Sneller has increased his personal stake further to over 10%. By way of reminder this guy is a professional fund manager with expertise in emerging markets. He has invested over £2m in ODX now. Talk about putting your money where your mouth is! Impressive endorsement

Haha how hypocritical. You were fawning over Harvinder before he left. And now you change your tune completely and knife him in the back. All it proves is that we, as investors, can change (indeed must in certain circumstances) change our mind about individual companies. It's not a relationship, a loved affair old chap. You sound like a jilted lover. Betrayal etc. Quite laughable really. Oh and as for my comments about India. They are true, always were but why would I knowingly s*it on my own doorstep at the time? Get real matey.

Someone else with their head in the trough now

This company is beyond a joke

Analysts Site Visit

Yep. So get on with it and get it out there asap! Since the market for CD4 is so big maybe they'd be better off selling at least part of the allergy business to fund the remaining development and bring to market costs of CD4? Anyone any thoughts?

Ignore him or, at the very least, take what HE says with an equal pinch of salt. To pretend he doesn't have his own personal agendas with individual companies is naive at best. That he is , somehow, batting for US the pi's is laughable in the extreme. He's just another market operator, but brands himself as "The Sheriff of AIM" lmfao. Then, in the next breath, describes it as a 'cesspit'?! Well Tom old boy if you're reading this let me remind you if you wallow about in the s*it you get covered with it yourself.

You know and I know that India is a terrible place to try and do business. Face the truth. That's why they're trying to diversify geographically. But it looks to me, from the SP, that the market smells a rat.

rivaldo - thanks - a very enlightening interview with management. I see the SP has edged down on virtually nothing. It's frustrating. The market is either ignoring, or doesn't get the potential here - now on THREE fronts: 1. Sale of Allergy business creating shareholder value by monetising asset 2. Growth and development of Allergy business (if kept with new commercial deal with IDS) 3. Commercialisation of CD4 tests 2017 with huge market I'm fortunate in that I can buy and hold - have patience. But it's coming. It's def coming.

But hoping for sub 10p

Look like they are flirting with the commencement of a classic aim downtrend. Look at the chart... H&S developing? I'll look to buy in @ 3-4p

Immunodiagnostic included this comment in their recent trading statement: 'The Group´s strategy to stop this decline is to expand our menu with CLIA assays not offered by the workhorses. With the number of different assays run on our instruments increasing, the iSYS should continue to be an attractive solution for laboratories to automate their specialty assays.' Significant? In relation to ODX statement today?

rivaldo - according to IDH most recent trading statement they have £28.7m in cash sitting on their BS - not £26m. Their MC is around £60m so nearly half of it is cash alone (haven't checked if they have any debt yet but would assume if any, insignificant. There is something else interesting they put in their recent statement that I will copy and paste shortly once I've digested it.

Good morning! Yes I hadn't even got around to mentioning the positive financial outlook provided by the company. Your ballpark figures for a possible sale of the Allergy business look, on the face of it, plausible.

Looks bullish for the SP today. Anyone got an idea how much the Allergy business is worth?

One of the LTH's here losing patience? It happens...

Overdone. Fall here - overdone. Shanta have hedged way ahead and, if I recall correctly, at a premium to current gold price! I'll be looking to stock up at the current prices.

I think it's likely that the results are baked into the price currently - but would like to be proved wrong hopefully! The real game changers, as we know, are the two projects for CD4 and Allersys. I feel the company must emphasise the significant progress made and accentuate the positives, drawing market attention. A further update would be welcome. Any deals in the pipeline - news there would be good. We could, and should, be higher than this so Monday is an opportunity to move in the right direction.

Good morning :) No that's right. Doesn't take much buying or selling pressure to move this up or down. Results next Monday so possibly a bit of positioning. I'm hoping for a positive update to be included regarding the two commercialisation projects and Omega, please emphasise the positives and don't let them get buried in the detail!

If this is/will be punished due to their dependence on doing business in the USA (with Bullhorn amongst others) and Trumps stance on doing business with other countries.